Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

NCT07150299 · clinicaltrials.gov ↗

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hypertrophic Obstructive Cardiomyopathy \(HOCM\)

Interventions

DRUG: Mavacamten in clinical routine use

Sponsor

Medical University of Vienna